Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy
Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
The outcomes for patients with chronic myeloid leukemia have improved dramatically with the development and availability of BCR–ABL1 tyrosine kinase inhibitors (TKIs) over the past decade. TKI therapy has a superior safety profile compared with the previous standard of care, interferon-α, and most adverse events (AEs) observed with front-line and s...
Alternative Titles
Full title
Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3483619
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3483619
Other Identifiers
ISSN
2044-5385
E-ISSN
2044-5385
DOI
10.1038/bcj.2012.30
